Corcept Therapeutics Incorporated
CORT
$72.27
-$0.79-1.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.04% | 71.07% | -33.17% | -34.88% | 33.04% |
| Total Depreciation and Amortization | 1.71% | 1.52% | 0.43% | -7.82% | 152.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 58,567.92% | -100.82% | -40.15% | 645.26% | -10.79% |
| Change in Net Operating Assets | -60.02% | 137.53% | -228.63% | -37.04% | 278.41% |
| Cash from Operations | 23.99% | 756.84% | -91.35% | -19.09% | 77.95% |
| Capital Expenditure | 100.00% | 45.19% | 14.05% | 92.60% | -293.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.13% | 2,388.36% | 95.23% | -51.50% | 29.07% |
| Cash from Investing | -79.12% | 2,311.51% | 95.07% | -46.15% | 26.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -66.40% | 262.08% | 42.71% | 6.70% | -29.90% |
| Repurchase of Common Stock | 56.16% | -166.87% | -519.30% | 70.10% | -333.66% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 54.91% | -158.61% | -772.11% | 78.36% | -881.02% |
| Foreign Exchange rate Adjustments | -117.84% | -- | -- | -- | 9,033.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 73.24% | 134.15% | -293.25% | -210.61% | 141.12% |